Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inzomelid in Healthy Adults and CAPS Patients
NCT04015076Phase 1Completed
- Sponsor
- Inflazome
- Start
- Jul 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of inzomelid in Cryopyrin-associated periodic syndromes (CAPS) (3 arms), sponsored by Inflazome. Primary endpoints: Incidence of treatment emergent adverse events, Peak Plasma Concentration (Cmax) - Single Dose and 3 more. Started Jul 2019; status: completed.
02
Drugs
inzomelid
03
Conditions
Cryopyrin-associated periodic syndromes (CAPS)
Beyond the preview
Go deeper on NCT04015076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015076.